These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17686055)

  • 1. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
    Choi SH; Byun HM; Kwan JM; Issa JP; Yang AS
    Br J Haematol; 2007 Sep; 138(5):616-23. PubMed ID: 17686055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
    Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
    Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
    Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
    Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demethylation of DNA by decitabine in cancer chemotherapy.
    Brown R; Plumb JA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):501-10. PubMed ID: 15270655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
    Hurtubise A; Momparler RL
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells.
    Liu QY; Chen DW; Xie LP; Zhang RQ; Wang HZ
    Environ Toxicol Pharmacol; 2011 Nov; 32(3):423-9. PubMed ID: 22004962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
    Cowan LA; Talwar S; Yang AS
    Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
    Christman JK
    Oncogene; 2002 Aug; 21(35):5483-95. PubMed ID: 12154409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
    Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
    J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
    Egger G; Aparicio AM; Escobar SG; Jones PA
    Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Steele N; Finn P; Brown R; Plumb JA
    Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines.
    Schaefer M; Hagemann S; Hanna K; Lyko F
    Cancer Res; 2009 Oct; 69(20):8127-32. PubMed ID: 19808971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of inhibition of DNA methylation by fludarabine.
    Wyczechowska D; Czyz M; Fabianowska-Majewska K
    Adv Exp Med Biol; 2000; 486():349-53. PubMed ID: 11783513
    [No Abstract]   [Full Text] [Related]  

  • 17. 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1.
    Byun HM; Choi SH; Laird PW; Trinh B; Siddiqui MA; Marquez VE; Yang AS
    Cancer Lett; 2008 Aug; 266(2):238-48. PubMed ID: 18499340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors.
    Nie J; Liu L; Li X; Han W
    Cancer Lett; 2014 Nov; 354(1):12-20. PubMed ID: 25130173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
    Issa JP; Gharibyan V; Cortes J; Jelinek J; Morris G; Verstovsek S; Talpaz M; Garcia-Manero G; Kantarjian HM
    J Clin Oncol; 2005 Jun; 23(17):3948-56. PubMed ID: 15883410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
    Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
    Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.